Olopatadine Rafarm

Olopatadine, the active ingredient in Olopatadine Rafram, is an antihistamine presented as a 0.1% ophthalmic solution for topical eye use. It treats allergic conjunctivitis and related ocular itching in adults and children. GNH USA supplies Olopatadine Rafram as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olopatadine Rafram as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olopatadine Rafram is an antihistamine that acts on ocular allergic reactions.

- Allergic conjunctivitis: Reduces eye redness, itching, and swelling. - Seasonal allergic eye disease: Alleviates symptoms triggered by pollen and seasonal allergens. - Vernal keratoconjunctivitis: Provides relief from chronic itching and photophobia. - Contact lens‑related irritation: Helps control mild allergic responses in contact lens wearers. - Post‑operative ocular inflammation: Supports comfort after eye surgery. - Ocular pruritus caused by environmental irritants : Offers symptomatic relief.

Olopatadine Rafram may cause a range of ocular and systemic reactions.

Common Side Effects: - Burning sensation: Mild transient burning upon instillation. - Stinging or discomfort: Temporary irritation after dosing. - Blurred vision: Short‑term visual haziness that resolves quickly. - Redness of the eye: Mild conjunctival hyperemia. - Tearing: Increased lacrimation. - Foreign‑body sensation: Feeling of grit or sand.

Serious or Rare Side Effects: - Severe allergic reaction: Anaphylaxis or angio‑edema requiring emergency care. - Persistent ocular pain: Ongoing discomfort beyond the initial administration period. - Corneal ulceration: Rare ulcer formation on the cornea. - Vision loss: Sudden decrease in visual acuity. - Intra‑ocular pressure rise: Uncommon increase in eye pressure. - Contact lens intolerance: Inability to wear lenses due to irritation.

When using Olopatadine Rafram, consider the following safety measures:

- Avoid self‑medication: Consult a healthcare professional before initiating therapy. - Monitor for hypersensitivity: Discontinue if signs of rash or swelling appear. - Use with caution in children: Safety data are limited for patients under 12 years. - Contact lens wearers: Remove lenses before instillation and wait before reinserting. - Pregnancy and lactation: Discuss the risk‑benefit of the treatment with the prescriber. - Store at ambient temperature: Keep the bottle below 25 °C, in the original pack and protect from light.

Olopatadine Rafram may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid):\n- Concomitant use ​        ​  ​   ​  ​  ​  ​   ​   ​     ​   ​   ​   ​  ​  ​-               ​   ​ -     

Moderate  

-